

Erratum: This corrects the article, “[Rationale and Design of the Roflumilast or Azithromycin to Prevent COPD Exacerbations Clinical Trial](#),” published in Volume 13, Issue 1, pp. 17-28.

Erratum

Jerry A. Krishnan, MD, PhD¹ Janet T. Holbrook, PhD² Elizabeth A. Sugar, PhD² Richard Albert, MD³ Steve Rennard, MD⁴
Nina Bracken, APRN¹ Jiaxian He, MS² Marie Bradley, PhD, MSc PH, MPharm⁵ Kevin Coughlin, MA⁶
Candace C. Fuller, PhD, MPH⁶ Bradley Hammill, DrPH, MA⁷ Elisha Malanga, BS⁸ Vincent M. Malanga, BS⁸
David Mannino, MD, MPH⁸ Richard A. Mularski, MD, MCR, MSHS⁹ Hugh Musick, MBA¹ Jean Rommes, PhD⁸
Julie DeLisa, MA¹ Sengwee Toh, ScD⁶ Robert A. Wise, MD²

1. Department of Medicine, University of Illinois Chicago, Chicago, Illinois, United States
2. Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland, United States
3. Department of Medicine, University of Colorado Anschutz, Aurora, Colorado, United States
4. Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States
5. U.S. Food and Drug Administration, Silver Spring, Maryland, United States
6. Harvard Pilgrim Health Care Institute, Boston, Massachusetts, United States
7. Department of Population Health Sciences, Duke University, Durham, North Carolina, United States
8. COPD Foundation, Miami, Florida, United States
9. Center for Health Research, Kaiser Permanente Northwest, Washington, D.C., United States

Citation:

Erratum. *Chronic Obstr Pulm Dis*. 2026; 13(5):439. doi: <https://doi.org/10.15326/jcopdf.2025.0669E>

In Volume 13, Issue 1 (January 2026), the article, “Rationale and Design of the Roflumilast or Azithromycin to Prevent COPD Exacerbations Clinical Trial” contained an error in the Materials and Methods section, Primary and Secondary Outcomes subsection, third sentence. This third sentence should have read:

“Secondary outcomes include (1) moderate COPD exacerbation, all-cause hospitalization, or all-cause death (secondary composite outcome); and (2) individual components of the primary and secondary composite outcomes: moderate COPD exacerbation, all-cause hospitalization, and all-cause death. Moderate exacerbation was defined as treatment with antibiotics or systemic corticosteroids for respiratory exacerbations not associated with a hospitalization.”

(The original incorrect description published was: “Secondary outcomes include the individual components of the composite outcome and COPD-related acute care events [hospitalization, emergency department visit, or urgent care visit].”)

The authors regret this error.

This correction has been made to the online and PDF versions of the article: <https://doi.org/10.15326/jcopdf.2025.0669>